Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting

About this update from Resverlogix Corp.

[{"type":"text","content":"\n\n\n\nTSX Exchange Symbol: RVX\n\n\nORLANDO, FL, Nov. 5 /CNW/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX)\nis pleased to announce today key scientific data was presented in an oral\npresentation highlighting the novel features of RVX-208, at the American Heart\nAssociation Scientific Meetings. The presentation titled "Oral Administration\nof Compound RVX-208 Increases Serum Levels of ApoA-I and Improves High-Density\nLipoprotein-Mediated Cholesterol Efflux in African Green Monkeys" was\npresented by Dr. Jacques Genest.\n\n\nDr. Jacques Genest, MD, Director of the Division of Cardiology at McGill\nUniversity Health Centre/Royal Victoria Hospital said, "We were excited about\nthis data and felt that it should be presented at this prestigious conference.\nResverlogix's novel drug demonstrated the ability to increase the production\nof ApoA-I and functional HDL. Notably we saw increases in pre beta HDL sub\nparticles, which improve HDL's ability to mediate cholesterol efflux."\n\n\n"We are very pleased to have our data presented at one of the most\nprestigious conferences for cardiovascular disease," stated Dr. Jan Johansson,\nMD, Ph.D., Senior Vice President, Clinical Affairs of Resverlogix. "Our small\nmolecule, RVX-208, by virtue of increasing endogenous production of ApoA-I and\nfunctional HDL has huge potential to address the unmet medical need of\ncardiovascular disease," added Dr Johansson.\n\n\nApolipoprotein A-I (ApoA-I), the main component of high-density\nlipoprotein (HDL) represent the bodies natural defense system against\natherosclerosis by mediating reverse cholesterol transport, i.e. transport of\nperipheral cholesterol including that of the vessel wall to the liver for\nprocessing. In multiple human and animal studies over-expression or repeated\ninfusion of ApoA-I inhibit progression and induce regression of\natherosclerosis in animals and humans. In his presentation Dr. Genest\ndiscussed the effects of oral administration of RVX-208 on serum ApoA-I\nlevels, HDL subspecies distribution and the functional improvements of serum\nto promote cellular cholesterol efflux from vulnerable plaque cells. The mere\nfact that the data is based on African Green monkeys in a context of\ndose-response makes it predictive for similar treatment effects in humans.\n\n\nAbout Card...

More updates from Resverlogix Corp.